Why Value-based Contracts Are Still the Exception, per Chester "Bernie" Good at UPMC

October 17, 2022

Chester "Bernie" Good, senior medical director for the Center for Value Based Pharmacy Initiatives at UPMC Health Plan, gets in depth on value-based contracts and shares the results of the 2019 contract between UPMC and AstraZeneca for Brilinta. Good addressed value-based contracts last week at AMCP Nexus 2022 conference in National Harbor, Maryland.

Will Keytruda and Opdivo Finally Get Some Price Competition? | AMCP Nexus 2022

October 14, 2022

EQRx has said it will price its PD-1/PDL-1 inhibitor 40% below the price of the entrenched PD-1/PDL-1 inhibitors, says Bhavesh Shah of Boston Medical Center Health System. But there are obstacles looming, including the development of combination therapies.

How to Make Accumulator, Maximizer Programs More Acceptable to Your Patients l AMCP Nexus 2022

October 14, 2022

Julie Kendle, Director, Clinical Pharmacy Director, Clinical Pharmacy at IPD Analytics addresses tips on improving accumulators and ways for PBMs or payers to make their accumulator and maximizer programs more acceptable to patients. Kendle spoke at this year's AMCP Nexus meeting in National Harbor, Maryland.

Trikafta Effective But Costly, Says Prime Therapeutics | AMCP Nexus 2022

October 14, 2022

A real-world study by the PBM shows major benefits from the new cystic fibrosis drug when it comes to hospitalizations and pulmonary exacerbations. But total cost of care of patients tripled because the drug is expensive.

Gene Therapy Has Arrived. But So Will the $$$$$ Bills. | AMCP Nexus 2022

October 13, 2022

Express Scripts' Aimee Tharaldson discussed the growing number of gene therapies in her keynote talk today on specialty drug at AMCP Nexus 2022. She listed 12 approved gene therapies, eight in the near-term pipeline for hemophilia and another seven for other diseases that may be approved next year.

Digital Therapeutics Should Have More to Come in Healthcare by 2023 | AMCP Nexus 2022

October 13, 2022

Kelly Price, vice president of market access for Mahana Therapeutics, compared the difference between digital therapeutics, prescription digital therapeutics and how FDA approval factors into that difference. She also shared what's hopeful and what's to come as far as coverage decisions, rule changes and FDA guidance for digital therapeutics in 2023.